Assembly Biosciences, Inc (ASMB) is a publicly traded Healthcare sector company. As of May 21, 2026, ASMB trades at $26.34 with a market cap of $435.78M and a P/E ratio of -239.08. ASMB moved -0.92% today. Year to date, ASMB is -18.72%; over the trailing twelve months it is +81.48%. Its 52-week range spans $7.75 to $39.71. Analyst consensus is strong buy with an average price target of $44.33. Rallies surfaces ASMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Assembly Biosciences to Present Phase 1a Safety Data on Oral HDV Entry Inhibitor ABI-6250: Assembly Biosciences will present topline Phase 1a safety, pharmacokinetic and pharmacodynamic data on its oral HDV entry inhibitor ABI-6250 at the EASL Congress in Barcelona May 27–30, 2026. These interim results support advancing ABI-6250 directly into a Phase 2 study by year-end as the only oral HDV entry inhibitor in development.
| Metric | Value |
|---|---|
| Price | $26.34 |
| Market Cap | $435.78M |
| P/E Ratio | -239.08 |
| EPS | $-0.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $39.71 |
| 52-Week Low | $7.75 |
| Volume | 337 |
| Avg Volume | 0 |
| Revenue (TTM) | $71.10M |
| Net Income | $-6.38M |
| Gross Margin | 0.00% |
3 analysts cover ASMB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.33.